Precision will be sponsoring, presenting and exhibiting at the World Pharma Pricing & Market Access Congress event in London, England.
Presenting: Precision for Value’s Andre Vidal Pinheiro, Senior Engagement Manager and Alex Grosvenor, Senior Principal will be leading a breakfast briefing on market access considerations for the adoption of biosimilars in Europe.
Breakfast briefing led by Precision for Value
Title: Market access considerations for the adoption of biosimilar anti-TNFs in Europe
Time: 8:00 a.m.
Summary: The recent introduction of biosimilar anti-TNFs has attracted considerable attention, with much of the commentary centering on price: how competitive discounting threatens pharma company revenue streams and will drive significant cost-savings for payers. But price only tells part of the story. In the case of infliximab, structural and perceptual differences have led to considerable heterogeneity in the levels of discounting and uptake across – and even within – European markets. Our exploratory research with both payers and clinicians (n=54), across nine key countries, explores the broader market access issues affecting the adoption of biosimilar anti-TNFs, enabling attendees to gain a deeper understanding of:
• Prescribing behavior across patient populations
• Role of clinical and payer guidelines
• Other payer controls and mechanisms
• Policies, funding pathways and other structural considerations
• Best practices for navigating the evolving market access landscape
